Transcranial magnetic stimulation (TMS) has evolved from a promising research technology into an established treatment option for depression in many healthcare systems. But how does a new treatment move from scientific evidence into routine clinical practice?

In this episode of the Neurocare Academy Podcast, Dr. Trevor Brown is joined by Dr. Mohamed Abdelghani, Consultant Psychiatrist, international TMS educator, former President of the Clinical TMS Society, and founder of one of London's earliest NHS TMS services. Together, they discuss the practical realities of introducing innovative treatments into healthcare systems and the lessons learned from helping establish TMS services within the NHS.

The conversation explores why health economics play a crucial role in driving adoption, why public and clinician awareness still lag behind the evidence, and how expanding access to TMS could help address the growing burden of treatment-resistant depression.

Dr. Abdelghani also shares his perspective on the future of neuromodulation, including accelerated TMS protocols, connectivity-guided treatment approaches, and emerging applications beyond depression.

In this episode:

• The journey of TMS from research to NHS implementation
• Building one of London's first NHS TMS services
• The role of health economics in healthcare innovation
• Challenges surrounding awareness and access to TMS
• Accelerated TMS and the future of treatment delivery
• Connectivity-guided neuromodulation
• Potential future applications in ADHD and other conditions

Key Takeaways

• TMS became NHS-funded in 2016 and continues to expand across the UK.
• Successfully implementing innovation requires clinical, operational, and economic expertise.
• Greater public awareness is essential if more patients are to benefit from evidence-based neuromodulation treatments.

Neurocare Academy features conversations with leading experts at the forefront of neuroscience, neuromodulation, and evidence-based mental healthcare.